Correlation Between Nurix Therapeutics and Gilead Sciences

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Nurix Therapeutics and Gilead Sciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nurix Therapeutics and Gilead Sciences into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Nurix Therapeutics and Gilead Sciences, you can compare the effects of market volatilities on Nurix Therapeutics and Gilead Sciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nurix Therapeutics with a short position of Gilead Sciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nurix Therapeutics and Gilead Sciences.

Diversification Opportunities for Nurix Therapeutics and Gilead Sciences

-0.27
  Correlation Coefficient

Very good diversification

The 3 months correlation between Nurix and Gilead is -0.27. Overlapping area represents the amount of risk that can be diversified away by holding Nurix Therapeutics and Gilead Sciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Gilead Sciences and Nurix Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nurix Therapeutics are associated (or correlated) with Gilead Sciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Gilead Sciences has no effect on the direction of Nurix Therapeutics i.e., Nurix Therapeutics and Gilead Sciences go up and down completely randomly.

Pair Corralation between Nurix Therapeutics and Gilead Sciences

Given the investment horizon of 90 days Nurix Therapeutics is expected to under-perform the Gilead Sciences. In addition to that, Nurix Therapeutics is 3.84 times more volatile than Gilead Sciences. It trades about -0.05 of its total potential returns per unit of risk. Gilead Sciences is currently generating about -0.1 per unit of volatility. If you would invest  9,340  in Gilead Sciences on October 22, 2024 and sell it today you would lose (156.00) from holding Gilead Sciences or give up 1.67% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Nurix Therapeutics  vs.  Gilead Sciences

 Performance 
       Timeline  
Nurix Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Nurix Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's forward indicators remain fairly strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Gilead Sciences 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Gilead Sciences are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound essential indicators, Gilead Sciences is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders.

Nurix Therapeutics and Gilead Sciences Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Nurix Therapeutics and Gilead Sciences

The main advantage of trading using opposite Nurix Therapeutics and Gilead Sciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nurix Therapeutics position performs unexpectedly, Gilead Sciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Gilead Sciences will offset losses from the drop in Gilead Sciences' long position.
The idea behind Nurix Therapeutics and Gilead Sciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Complementary Tools

Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years